Published on
November 4, 2025
- 14:00 GMT
PhenoNet, Initiating A Phase IIb study in ALs Subjects
Our current clinical study targets early-stage patients with defined progression profiles, representing a more precise approach to developing ALS drugs. CAMBRIDGE, MA, UNITED STATES, November 4, 2025 /EINPresswire.com/ -- Cambridge, MA-based …
Distribution channels:
Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry
...
